NCT04966325View on ClinicalTrials.gov

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
HyperuricemiaGoutQt Interval, Variation in
Interventions
DRUG

LC350189 200mg

Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

DRUG

Placebo

Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

DRUG

Moxifloxacin 400mg

Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

DRUG

LC350189 600mg

Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

Trial Locations (1)

78744

PPD, Austin

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter